NO20010576L - Immunologiske herpes simplex virus antigener og fremgangsmÕter for anvendelse derav - Google Patents
Immunologiske herpes simplex virus antigener og fremgangsmÕter for anvendelse deravInfo
- Publication number
- NO20010576L NO20010576L NO20010576A NO20010576A NO20010576L NO 20010576 L NO20010576 L NO 20010576L NO 20010576 A NO20010576 A NO 20010576A NO 20010576 A NO20010576 A NO 20010576A NO 20010576 L NO20010576 L NO 20010576L
- Authority
- NO
- Norway
- Prior art keywords
- antigens
- hsv
- cells
- immunological
- methods
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 7
- 102000036639 antigens Human genes 0.000 title abstract 7
- 108091007433 antigens Proteins 0.000 title abstract 7
- 241000700584 Simplexvirus Species 0.000 title 1
- 230000001900 immune effect Effects 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 208000009889 Herpes Simplex Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 210000003679 cervix uteri Anatomy 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Oppfinnelsen tilveiebringer HSV antigener som er nyttige for å forebygge og behandle HSV infeksjon. Angitt heri er antigener og/eller deres konstituente epitoper bekreftet å være gjenkjent av T-celler avledet fra herpes lesjoner eller fra livmorhalsen. T-celler som har spesifisitet for antigenene fra oppfinnelsen har vist cytotoksisk aktivitet mot celler som har viral-kodede peptid epitoper, og i mange tilfeller, mot celler infisert med HSV. Identifiseringen av immunogene antigener som er ansvarlig for T-celle spesifisitet tilveiebringer forbedret antiviral terapeutika og profylaktiske strategier. Sammensetninger som inneholder antigener eller polynukleotider som koder for antigener fra oppfinnelsen tilveiebringer effektive mål økende vaksiner for å forebygge og behandle HSV infeksjon.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9572498P | 1998-08-07 | 1998-08-07 | |
US9572398P | 1998-08-07 | 1998-08-07 | |
PCT/US1999/017803 WO2000008051A2 (en) | 1998-08-07 | 1999-08-05 | Immunological herpes simplex virus antigens and methods for use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20010576D0 NO20010576D0 (no) | 2001-02-02 |
NO20010576L true NO20010576L (no) | 2001-04-02 |
Family
ID=26790525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20010576A NO20010576L (no) | 1998-08-07 | 2001-02-02 | Immunologiske herpes simplex virus antigener og fremgangsmÕter for anvendelse derav |
Country Status (16)
Country | Link |
---|---|
US (5) | US6375952B1 (no) |
EP (2) | EP1102790B1 (no) |
JP (1) | JP2002522451A (no) |
KR (1) | KR20010085348A (no) |
CN (1) | CN1348463A (no) |
AR (1) | AR020134A1 (no) |
AU (1) | AU5467899A (no) |
BR (1) | BR9912671A (no) |
CA (1) | CA2336523C (no) |
DK (1) | DK2272859T3 (no) |
IL (1) | IL141044A0 (no) |
NO (1) | NO20010576L (no) |
NZ (1) | NZ509974A (no) |
PL (1) | PL346213A1 (no) |
TR (1) | TR200100373T2 (no) |
WO (1) | WO2000008051A2 (no) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060024301A1 (en) * | 1997-02-25 | 2006-02-02 | Corixa Corporation | Prostate-specific polypeptides and fusion polypeptides thereof |
US20030185830A1 (en) * | 1997-02-25 | 2003-10-02 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US7517952B1 (en) | 1997-02-25 | 2009-04-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
BR9912671A (pt) * | 1998-08-07 | 2001-05-02 | Univ Washington | Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização |
US7223593B2 (en) | 2000-01-21 | 2007-05-29 | Biovex Limited | Herpes virus strains for gene therapy |
US7217770B2 (en) * | 2000-05-17 | 2007-05-15 | Samyang Corporation | Stable polymeric micelle-type drug composition and method for the preparation thereof |
US6821519B2 (en) * | 2000-06-29 | 2004-11-23 | Corixa Corporation | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
US7048931B1 (en) * | 2000-11-09 | 2006-05-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
WO2003011893A2 (en) * | 2001-07-31 | 2003-02-13 | University Of Washington | Immunologically significant herpes simplex virus antigens and methods for using same |
EP2011510B1 (en) | 2002-07-18 | 2011-01-12 | University of Washington | Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments |
JP2007505147A (ja) * | 2003-09-12 | 2007-03-08 | アンティジェニクス インコーポレーテッド | 単純ヘルペスウイルス感染の治療および予防用ワクチン |
US7211272B2 (en) * | 2003-12-22 | 2007-05-01 | Bausch & Lomb Incorporated | Drug delivery device |
CA2658484A1 (en) | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions and methods for vaccinating against hsv-2 |
US8871223B2 (en) * | 2006-09-08 | 2014-10-28 | The Trustees Of The University Of Pennsylvania | HSV-1 and HSV-2 vaccines and methods of use thereof |
WO2008124055A1 (en) | 2007-04-04 | 2008-10-16 | The Board Of Trustees Of The University Of Arkansas | Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection |
US8460674B2 (en) * | 2009-02-07 | 2013-06-11 | University Of Washington | HSV-1 epitopes and methods for using same |
WO2010115172A2 (en) | 2009-04-03 | 2010-10-07 | University Of Washington | Antigenic peptide of hsv-2 and methods for using same |
RU2585961C9 (ru) | 2009-05-22 | 2016-12-27 | Дженосеа Биосайенсиз Инк. | Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа |
WO2012061637A2 (en) * | 2010-11-03 | 2012-05-10 | University Of Washington | Hsv-1 epitopes and methods for using same |
AU2011336894B2 (en) | 2010-11-24 | 2016-11-17 | Genocea Biosciences, Inc. | Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response |
AU2012217723A1 (en) | 2011-02-15 | 2013-08-29 | Immune Design Corp. | Methods for enhancing immunogen specific immune responses by vectored vaccines |
CA2832307A1 (en) * | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
WO2012149307A2 (en) * | 2011-04-27 | 2012-11-01 | Immune Design Corp. | Synthetic long peptide (slp)-based vaccines |
JP6205360B2 (ja) | 2011-08-22 | 2017-09-27 | ナノバイオ コーポレーション | 単純ヘルペスウイルスのナノエマルジョンワクチン |
CA2885693C (en) | 2011-11-23 | 2020-07-28 | Genocea Biosciences, Inc. | Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
EP2850431B1 (en) * | 2012-05-16 | 2018-04-18 | Immune Design Corp. | Vaccines for hsv-2 |
WO2014164699A1 (en) * | 2013-03-11 | 2014-10-09 | The Regents Of The University Of California | Herpes virus vaccines and treatments |
CA2939093A1 (en) | 2014-02-14 | 2015-08-20 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
US20170196954A1 (en) | 2014-07-15 | 2017-07-13 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
KR20160073707A (ko) | 2014-12-17 | 2016-06-27 | 삼성중공업 주식회사 | 액화천연가스 운반선의 운용방법 |
JP6760973B2 (ja) | 2015-02-26 | 2020-09-23 | スクエアエックス、 エルエルシー | 単純ヘルペスウイルス感染治療のための非特異的遅延型過敏反応 |
RS62747B1 (sr) * | 2016-02-01 | 2022-01-31 | Simplexia Ab | Skraćeni glikoprotein g herpes simpleks virusa 2 |
EP3429619A1 (en) * | 2016-03-14 | 2019-01-23 | Redbiotec AG | Means and methods for treating hsv |
KR20190006495A (ko) | 2016-04-15 | 2019-01-18 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Cd80 변이체 면역조절 단백질 및 그의 용도 |
AU2017250358B2 (en) | 2016-04-15 | 2023-06-01 | Alpine Immune Sciences, Inc. | ICOS ligand variant immunomodulatory proteins and uses thereof |
WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
CN110088127A (zh) | 2016-07-28 | 2019-08-02 | 高山免疫科学股份有限公司 | Cd155变体免疫调节蛋白及其用途 |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
WO2018064232A1 (en) | 2016-09-28 | 2018-04-05 | Genocea Biosciences, Inc. | Methods and compositions for treating herpes |
JP2020511144A (ja) | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Pd−l2バリアント免疫調節タンパク質及びその使用 |
BR112019018747A2 (pt) | 2017-03-16 | 2020-05-05 | Alpine Immune Sciences Inc | proteínas imunomoduladoras variantes de cd80 e usos das mesmas |
CA3053804A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l1 variant immunomodulatory proteins and uses thereof |
CN110506060B (zh) | 2017-03-30 | 2024-05-07 | 昆士兰大学 | 嵌合分子及其用途 |
US20190031739A1 (en) * | 2017-07-30 | 2019-01-31 | Raymond Joel Rairie | Pinball herpes antibody system |
EP3687561A4 (en) | 2017-09-01 | 2021-06-09 | The Australian National University | IMMUN REGULATORY MOLECULES AND THEIR USES |
KR20230020022A (ko) | 2017-10-10 | 2023-02-09 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
KR20200085777A (ko) | 2017-10-18 | 2020-07-15 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 변이체 icos 리간드 면역조절 단백질 및 관련 조성물 및 방법 |
CA3087149A1 (en) | 2018-01-03 | 2019-07-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
SG11202102644XA (en) | 2018-09-19 | 2021-04-29 | Alpine Immune Sciences Inc | Methods and uses of variant cd80 fusion proteins and related constructs |
CN113727998A (zh) | 2018-11-30 | 2021-11-30 | 高山免疫科学股份有限公司 | Cd86变体免疫调节蛋白及其用途 |
BR112021020447A2 (pt) | 2019-04-17 | 2022-05-17 | Alpine Immune Sciences Inc | Métodos e usos de proteínas de fusão de ligante icos variante (icosl) |
KR20230029622A (ko) | 2020-05-08 | 2023-03-03 | 알파인 이뮨 사이언시즈, 인코포레이티드 | April 및 baff 억제 면역조절 단백질 및 사용 방법 |
IL308336A (en) | 2021-05-07 | 2024-01-01 | Alpine Immune Sciences Inc | Methods of dosing and treatment with TACI-FC modulatory fusion protein |
WO2023172883A1 (en) | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
CN115808528B (zh) * | 2022-09-21 | 2023-08-01 | 武汉滨会生物科技股份有限公司 | 溶瘤单纯疱疹病毒vp5蛋白与人白细胞抗原e的互作方法及应用 |
WO2024077018A2 (en) | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4429008B1 (en) | 1981-12-10 | 1995-05-16 | Univ California | Thiol reactive liposomes |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
JPS59116229A (ja) | 1982-12-24 | 1984-07-05 | Teijin Ltd | 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法 |
US4873088A (en) | 1983-09-06 | 1989-10-10 | Liposome Technology, Inc. | Liposome drug delivery method and composition |
US4859587A (en) | 1984-06-04 | 1989-08-22 | Institut Merieux | Recombinant herpes simplex viruses, vaccines and methods |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4699784A (en) | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
EP0297924A3 (en) * | 1987-07-01 | 1990-07-11 | City Of Hope | Recombinant vaccinia virus expressing hsv 1 gb |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
WO1991002805A2 (en) | 1989-08-18 | 1991-03-07 | Viagene, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
EP0541692B1 (en) | 1990-08-02 | 1999-05-06 | Chiron Corporation | Herpes simplex virus vp16 vaccines |
JPH05236967A (ja) * | 1991-05-07 | 1993-09-17 | Medical Res Council | ヘルペスウイルス粒子及びワクチン |
CA2090295A1 (en) | 1992-02-03 | 1993-08-04 | Anthony B. Nesburn | Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use |
ES2108278T3 (es) | 1992-06-25 | 1997-12-16 | Smithkline Beecham Biolog | Composicion de vacuna con coadyuvantes. |
US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
GB9325496D0 (en) * | 1993-12-14 | 1994-02-16 | Smithkline Beecham Biolog | Vaccines |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
ATE328890T1 (de) | 1994-07-15 | 2006-06-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
AU711121B2 (en) * | 1995-02-21 | 1999-10-07 | Cantab Pharmaceuticals Research Limited | Viral preparations, vectors, immunogens, and vaccines |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
JPH11510386A (ja) | 1995-07-28 | 1999-09-14 | マリー キュリー キャンサー ケア | 輸送蛋白質およびそれらの使用 |
WO1997024447A1 (en) | 1996-01-02 | 1997-07-10 | Chiron Corporation | Immunostimulation mediated by gene-modified dendritic cells |
GB9615726D0 (en) * | 1996-07-26 | 1996-09-04 | Medical Res Council | Anti-viral agent 11 |
EP0948508A4 (en) * | 1996-11-04 | 2001-11-07 | Smithkline Beecham Corp | NEW CODING SEQUENCES FOR HERPES SIMPLEX TYPE 2 VIRUS |
CA2291010A1 (en) * | 1997-06-02 | 1998-12-10 | Chiron Corporation | Herpes simplex virus vp22 vaccines and methods of use |
BR9912671A (pt) * | 1998-08-07 | 2001-05-02 | Univ Washington | Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização |
GB9825953D0 (en) * | 1998-11-26 | 1999-01-20 | Medical Res Council | Protein fragments for use in protein targeting |
CA2379623C (en) * | 1999-09-30 | 2014-09-09 | University Of Washington | Immunologically significant herpes simplex virus antigens |
US6821519B2 (en) | 2000-06-29 | 2004-11-23 | Corixa Corporation | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
EP2011510B1 (en) * | 2002-07-18 | 2011-01-12 | University of Washington | Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments |
CA2658484A1 (en) | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions and methods for vaccinating against hsv-2 |
US8865185B2 (en) | 2006-09-08 | 2014-10-21 | The Trustees Of The University Of Pennsylvania | Methods of use for HSV-1 and HSV-2 vaccines |
-
1999
- 1999-08-05 BR BR9912671-0A patent/BR9912671A/pt not_active IP Right Cessation
- 1999-08-05 TR TR2001/00373T patent/TR200100373T2/xx unknown
- 1999-08-05 NZ NZ509974A patent/NZ509974A/en not_active IP Right Cessation
- 1999-08-05 WO PCT/US1999/017803 patent/WO2000008051A2/en not_active Application Discontinuation
- 1999-08-05 CN CN99810454A patent/CN1348463A/zh active Pending
- 1999-08-05 JP JP2000563684A patent/JP2002522451A/ja not_active Withdrawn
- 1999-08-05 EP EP99940918.8A patent/EP1102790B1/en not_active Expired - Lifetime
- 1999-08-05 IL IL14104499A patent/IL141044A0/xx unknown
- 1999-08-05 CA CA2336523A patent/CA2336523C/en not_active Expired - Fee Related
- 1999-08-05 DK DK10182295.5T patent/DK2272859T3/en active
- 1999-08-05 EP EP10182295.5A patent/EP2272859B1/en not_active Expired - Lifetime
- 1999-08-05 PL PL99346213A patent/PL346213A1/xx not_active Application Discontinuation
- 1999-08-05 KR KR1020017001641A patent/KR20010085348A/ko not_active IP Right Cessation
- 1999-08-05 US US09/368,770 patent/US6375952B1/en not_active Expired - Lifetime
- 1999-08-05 AU AU54678/99A patent/AU5467899A/en not_active Abandoned
- 1999-08-06 AR ARP990103950A patent/AR020134A1/es not_active Application Discontinuation
-
2001
- 2001-02-02 NO NO20010576A patent/NO20010576L/no unknown
-
2002
- 2002-02-11 US US10/073,834 patent/US6855317B2/en not_active Expired - Fee Related
-
2005
- 2005-02-10 US US11/055,477 patent/US7744903B2/en not_active Expired - Fee Related
-
2010
- 2010-05-10 US US12/777,156 patent/US8067010B2/en not_active Expired - Fee Related
-
2011
- 2011-10-18 US US13/276,166 patent/US8852602B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
BR9912671A (pt) | 2001-05-02 |
NZ509974A (en) | 2003-10-31 |
EP1102790A2 (en) | 2001-05-30 |
KR20010085348A (ko) | 2001-09-07 |
WO2000008051A2 (en) | 2000-02-17 |
US8852602B2 (en) | 2014-10-07 |
US20100215693A1 (en) | 2010-08-26 |
EP2272859B1 (en) | 2014-10-22 |
AU5467899A (en) | 2000-02-28 |
CA2336523C (en) | 2015-06-30 |
US7744903B2 (en) | 2010-06-29 |
US20030118611A1 (en) | 2003-06-26 |
JP2002522451A (ja) | 2002-07-23 |
CN1348463A (zh) | 2002-05-08 |
DK2272859T3 (en) | 2015-01-19 |
US8067010B2 (en) | 2011-11-29 |
NO20010576D0 (no) | 2001-02-02 |
TR200100373T2 (tr) | 2001-09-21 |
US20050163794A1 (en) | 2005-07-28 |
IL141044A0 (en) | 2002-02-10 |
US6375952B1 (en) | 2002-04-23 |
US6855317B2 (en) | 2005-02-15 |
EP2272859A3 (en) | 2011-06-08 |
EP1102790B1 (en) | 2014-05-07 |
WO2000008051A3 (en) | 2000-08-03 |
CA2336523A1 (en) | 2000-02-17 |
EP2272859A2 (en) | 2011-01-12 |
AR020134A1 (es) | 2002-04-10 |
PL346213A1 (en) | 2002-01-28 |
US20120027790A1 (en) | 2012-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20010576L (no) | Immunologiske herpes simplex virus antigener og fremgangsmÕter for anvendelse derav | |
BR0014408A (pt) | Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos | |
Vollmar et al. | Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine | |
Clements et al. | The epidemiology of measles: thirty years of vaccination | |
ES2224655T3 (es) | Vacuna antiviral recombinante de la encefalitis equina venezolana. | |
FR16C0026I1 (no) | ||
WO2003011893A3 (en) | Immunologically significant herpes simplex virus antigens and methods for using same | |
DK1349926T3 (da) | Komplementerende cellelinier | |
NO331825B1 (no) | HPV viruslignende partikkel samt vaksine | |
EA027784B1 (ru) | Комбинированная вакцина против кори и вируса папилломы человека | |
ATE179614T1 (de) | Herpes simplex virus vp16 impfstoffe | |
UA84667C2 (ru) | Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека | |
WO2009150281A1 (es) | Empleo de lauril galato en la prevención y tratamiento de infecciones causadas por el virus de la peste porcina africana (vppa) | |
Fernández‐Parrado et al. | Monkeypox vaccine: Special considerations for dermatologic patients. | |
CA2245545A1 (en) | Vaccines against varicella zoster virus gene 63 product | |
US20240156951A1 (en) | Vaccine compositions and methods for treating hsv | |
HU228401B1 (en) | Smallpox vaccine | |
WO2004009763A2 (en) | Use of vaccinia virus deleted for the e3l gene as a vaccine vector | |
Lasky | From virus to vaccine: recombinant mammalian cell lines as substrates for the production of herpes simplex virus vaccines | |
Thomson | IMMUNOLOGICAL AND PROTECTIVE RESPONSES TO A HERPES SIMPLEX VIRUS SUBUNIT VACCINE IN A LABIAL INFECTION MODEL IN MICE. | |
WO2003017943A3 (en) | Therapeutic compositions and methods for treating viral infection | |
Hanke | Vehicles for Genetic Vaccines Against Human Immunodeficiency Virus Induction of T Cell-mediated Immune Responses | |
Rooney et al. | Prospects for treatment and prevention of latent herpes simplex virus infection | |
Kapoor et al. | Effect of certain purine and pyrimidine analogues on growth, nucleic acid synthesis and ultraviolet-induced lysis in Vibrio cholerae | |
AU2390101A (en) | Toscana virus nucleoprotein |